Native Clostridium difficile Toxoid B protein is a Clostridium difficile Full Length protein, expressed in Native, with >95% purity and suitable for SDS-PAGE, ELISA.
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Application ELISA | Reactivity Reacts | Dilution info - | Notes - |
Toxin B. Precursor of a cytotoxin that targets and disrupts the colonic epithelium, inducing the host inflammatory and innate immune responses and resulting in diarrhea and pseudomembranous colitis (PubMed:20844489, PubMed:24919149). TcdB constitutes the main toxin that mediates the pathology of C.difficile infection, an opportunistic pathogen that colonizes the colon when the normal gut microbiome is disrupted (PubMed:19252482, PubMed:20844489). Compared to TcdA, TcdB is more virulent and more important for inducing the host inflammatory and innate immune responses (PubMed:19252482, PubMed:24919149). This form constitutes the precursor of the toxin: it enters into host cells and mediates autoprocessing to release the active toxin (Glucosyltransferase TcdB) into the host cytosol (PubMed:10768933, PubMed:11152463, PubMed:12941936, PubMed:17334356, PubMed:20498856). Targets colonic epithelia by binding to the frizzled receptors FZD1, FZD2 and FZD7, and enters host cells via clathrin-mediated endocytosis (PubMed:27680706). Frizzled receptors constitute the major host receptors in the colonic epithelium, but other receptors, such as CSPG4 or NECTIN3/PVRL3, have been identified (PubMed:25547119, PubMed:26038560, PubMed:27680706). Binding to carbohydrates and sulfated glycosaminoglycans on host cell surface also contribute to entry into cells (By similarity). Once entered into host cells, acidification in the endosome promotes the membrane insertion of the translocation region and formation of a pore, leading to translocation of the GT44 and peptidase C80 domains across the endosomal membrane (PubMed:11152463, PubMed:12941936, PubMed:24567384). This activates the peptidase C80 domain and autocatalytic processing, releasing the N-terminal part (Glucosyltransferase TcdB), which constitutes the active part of the toxin, in the cytosol (PubMed:17334356, PubMed:27571750). Glucosyltransferase TcdB. Active form of the toxin, which is released into the host cytosol following autoprocessing and inactivates small GTPases (PubMed:16157585, PubMed:17901056, PubMed:24905543, PubMed:24919149, PubMed:7777059, PubMed:8144660). Acts by mediating monoglucosylation of small GTPases of the Rho family (Rac1, RhoA, RhoB, RhoC, RhoG and Cdc42) in host cells at the conserved threonine residue located in the switch I region ('Thr-37/35'), using UDP-alpha-D-glucose as the sugar donor (PubMed:16157585, PubMed:17901056, PubMed:24905543, PubMed:24919149, PubMed:7777059). Monoglucosylation of host small GTPases completely prevents the recognition of the downstream effector, blocking the GTPases in their inactive form, leading to actin cytoskeleton disruption and cell death, resulting in the loss of colonic epithelial barrier function (PubMed:24919149, PubMed:7777059).
toxB, tcdB, Toxin B
Native Clostridium difficile Toxoid B protein is a Clostridium difficile Full Length protein, expressed in Native, with >95% purity and suitable for SDS-PAGE, ELISA.
pH: 7 - 8
Constituents: 5% Sucrose, 1.19% HEPES, 0.88% Sodium chloride
Toxin B
Belongs to the clostridial glucosylating toxin (LCGT) family.
Toxin B
Inactivation: Inactivated using formaldehyde. No cell rounding in the sensitive verocytotoxicity assay at 2µg/ml compared to active toxin lethal dose of 4pg/ml.
Antigenicity: Maintained to be no less than 90% of original toxin strength as measured by direct ELISA.
This protein is derived from a pathogenic organism, and may be involved in a disease process, consequently exposure may have adverse health effects.
Clostridium difficile Toxoid B commonly referred to as TcdB is a large protein with a molecular mass around 270 kDa. It is expressed in the bacterium Clostridioides difficile an anaerobic pathogen found in the gut microbiota. Mechanically TcdB functions as a potent exotoxin that enters host cells and disrupts cellular processes by glucosylating Rho family GTPases which inhibits their activity. This action leads to a cascade of intracellular events including the disruption of actin cytoskeleton and cell rounding culminating in loss of cell-cell adhesion and eventually cell death.
TcdB acts as an important virulence factor of Clostridioides difficile infection contributing to the disease's pathogenesis by causing extensive intestinal damage. The toxin is not part of a multi-protein complex; it independently enters host cells using receptor-mediated endocytosis. Once inside it modifies important small GTPases that regulate the cytoskeleton leading to epithelial barrier dysfunction. The rapid cell damage caused by TcdB promotes inflammation and sets the stage for the onset of symptoms associated with Clostridioides difficile infections such as diarrhea and pseudomembranous colitis.
TcdB significantly impacts signaling pathways that control the cytoskeleton and cellular adhesion. Its glucosylation of Rho family GTPases inactivates them effectively disrupting the Rho/Rock signaling pathway pivotal for maintaining cytoskeletal structure. This alteration compromises intercellular junctions and increases intestinal permeability. Additionally TcdB interacts with Rac1 and CDC42 further contributing to disruption in cell cycle regulation and immune response modulation within the gut epithelium.
TcdB is strongly related to Clostridioides difficile-associated diseases particularly antibiotic-associated diarrhea and colitis. The toxin is linked to the pathogenesis of these conditions due to its role in gut epithelial damage and inflammation. Furthermore TcdB's interaction with various host proteins including RhoA Rac1 and CDC42 exacerbates tissue injury and immune responses facilitating the progression of these disorders. Understanding TcdB's function and interactions aids in developing therapeutic interventions targeting TcdB to mitigate the impact of these serious gastrointestinal diseases.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
SDS-PAGE showing ab124002 at 270kDa.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com